TNFRSF5/CD40
TNFRSF5/CD40 is a tumor necrosis factor receptor family member expressed by B cells, professional antigen-presenting cells, non-immune cells, and tumors[1]. Mechanistically, CD40-CD40L/CD154 engagement regulates humoral and cellular adaptive immunity, including B-cell proliferation, immunoglobulin isotype switching, and germinal center formation[1][2]. CD40 signaling recruits TRAFs and activates NF-κB, with additional involvement of PI3K/AKT, MAPKs, and JAK3/STAT pathways[3]. In inflammatory disease models, CD40 ligation promotes cytokines, chemokines, matrix metalloproteinases, growth factors, adhesion molecules, and procoagulant responses in vascular and immune-associated cells[4][5]. Compared with related pathway forms, CD40 and CD40L both have membrane and soluble forms, and soluble CD40 may bind CD40L and reduce transmembrane CD40 receptor activation[3][6]. For experimental applications, CD40 agonistic antibodies and CD40L-based strategies require receptor clustering or trimerization, while antagonistic approaches target autoimmune disease, allograft rejection, and inflammatory pathology[3][7].
参考文献:
- [1]. Elgueta R, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72. [Content Brief]
- [2]. Lougaris V, et al. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev. 2005 Feb;203:48-66. [Content Brief]
- [3]. Tang T, et al. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021 Mar;219:107709. [Content Brief]
- [4]. Chatzigeorgiou A, et al. CD40/CD40L signaling and its implication in health and disease. Biofactors. 2009 Nov-Dec;35(6):474-83. [Content Brief]
- [5]. Schönbeck U, et al. CD40 signaling and plaque instability. Circ Res. 2001 Dec 7;89(12):1092-103. [Content Brief]
- [6]. Lakshman N, et al. Microglia in the spinal cord stem cell niche regulate neural precursor cell proliferation via soluble CD40 in response to myelin basic protein. Stem Cells. 2025 Feb 12;43(2):sxae076. [Content Brief]
- [7]. Richards DM, et al. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16(2):377-387. [Content Brief]
-
TNFRSF5/CD40 関連製品 (142)
関連製品 (142)
-
Anti-inflammatory agent 17
0 Images製品番号: HY-146547CAS 番号: 2763226-84-0Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI).
-
Phoxim-d5 (phenyl-d5) (mixture of isomers)
0 Images製品番号: HY-W758414Phoxim-d5 (phenyl-d5) (mixture of isomers) is the deuterated-labeled Phoxim (HY-B0819). Phoxim is an organophosphorus pesticide and an orally active inhibitor of cholinesterase and CYP3A, which induces neurotoxicity in Caenorhabditis elegans and causes nephrotoxicity characterized by glomerular atrophy and interstitial fibrosis. Phoxim induces inhibition of the autophagy pathway. Phoxim induces dopaminergic neuron degeneration and exacerbates Aβ-induced paralysis. Phoxim damages enterocytes and disrupts intestinal barrier integrity. Phoxim induces ROS accumulation. Phoxim induces mitochondrial apoptosis, involving upregulation of Bad, Bax, caspase-3, and caspase-9 and downregulation of Bcl-2. Phoxim inhibits mitochondrial functional enzymes (COX, Ca2+-Mg2+-ATPase, SDH). Phoxim upregulates Nrf2 mRNA expression in the jejunal mucosa. Phoxim increases TNF-α and decreases IL-6 and IL-8 in the intestinal mucosa. Phoxim alters gut microbial composition by increasing total bacteria and Escherichia coli and reducing Lactobacillus. Phoxim enhances energy metabolism in silver carp by upregulating key glycolytic and gluconeogenic enzymes. Phoxim is used in research on neurodegenerative diseases, nephrotoxicity, intestinal oxidative stress and barrier dysfunction, and bacterial sepsis.
-
Oxoglaucine
0 ImagesOxoglaucine (O-Methylatheroline) is a natural product with multiple activities including autophagy activation, anti-inflammation, antibacterial activity, and immunoregulation. Oxoglaucine inhibits the TRPV5/calmodulin/CAMK-II pathway, suppresses TGFβ-induced Smad2 phosphorylation by upregulating Smad7, blocks Ca2+ influx, activates autophagy, alleviates apoptosis and inflammation, inhibits ROS production and the expression of fibrosis markers in hepatocytes, and regulates immune cell populations and responses. Oxoglaucine protects against infections caused by Candida albicans and Klebsiella pneumoniae, and exerts effects on adjuvant-induced arthritis. Oxoglaucine can be used in studies related to arthritis, liver fibrosis, bacterial infections, and fungal infections.
-
COX-2/5-LOX-IN-8
0 Images製品番号: HY-183764COX-2/5-LOX-IN-8 is an orally active dual COX-2/5-LOX inhibitor, with an IC50 of 6.30 μM against sheep-derived COX-2 and an IC50 of 8.09 μM against 5-LOX. COX-2/5-LOX-IN-8 acts as a membrane stabilizer that stabilizes erythrocyte membranes against hypotonicity-induced hemolysis. COX-2/5-LOX-IN-8 functions as a protein stabilizer that inhibits heat-induced denaturation of bovine serum albumin. COX-2/5-LOX-IN-8 reduces paw swelling, improves hind limb weight-bearing function, decreases serum levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, CRP), and lowers serum levels of cartilage degradation biomarkers (COMP, MMP-3, CTX-II). COX-2/5-LOX-IN-8 can be used in the research of osteoarthritis.
-
Neuroprotective agent 18
0 Images製品番号: HY-184935Neuroprotective agent 18 is a potent neuroprotective agent. Neuroprotective agent 18 inhibits the activity of NF-κB thereby significantly downregulating the expression of downstream pro-inflammatory mediators (TNF-α, IL-6) and inflammatory enzymes (COX-2) in the hippocampus. Neuroprotective agent 18 binds to AChE thereby partially inhibiting it and modulating cholinergic neurotransmission. Neuroprotective agent 18 can be used in research on Alzheimer's disease.
-
CDX-1140
0 Images製品番号: HY-P991510純度: 99.50%CDX-1140 is a fully human IgG monoclonal antibody and CD40 agonist, with a Kd value of 0.01 nM against human targets. The epitope of CDX-1140 locates at CD40 CRD1 and avoids the CD40L binding site. It activates DCs and B cells, drives NF-κB reporter gene activation, exhibits agonist activity independent of FcR cross-linking, and shows a synergistic effect with recombinant CD40L. CDX-1140 does not induce systemic cytokine release, exerts direct and immune-mediated anti-tumor activity in tumor xenografts, and has favorable safety profiles. When used as a local vaccine adjuvant in combination with 6MHP+mBRAF+poly-ICLC, CDX-1140 increases the number of DC-LAMP+ DCs and induces Th1 CD4+ responses in high-risk melanoma. CDX-1140 can be used in studies related to B-cell lymphoma, bladder cancer and high-risk melanoma.
-
Centella asiatica extract
0 Images製品番号: HY-N18667CAS 番号: 84696-21-9Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.
-
Tegoprubart (powder)
0 Images製品番号: HY-P990083ACAS 番号: 2628092-47-5別名: AT-1501 (powder)Tegoprubart (powder) (AT-1501 (powder)) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart (powder) suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart (powder) preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart (powder) is applicable to research related to kidney transplantation and kidney transplant rejection.
-
Anti-inflammatory agent 22
0 Images製品番号: HY-146435CAS 番号: 2721484-76-8Anti-inflammatory agent 22 (compound 14a) is an orally active anti-inflammatory agent. Anti-inflammatory agent 22 inhibits LPS-induced TNF-α production with an IC50 value of 14.6 μM. Anti-inflammatory agent 22 has preventive effects on lymphedematous tissue via suppression of adipogenesis. Anti-inflammatory agent 22 suppresses limb lymphedema volume in mice.
-
IDO1/TDO-IN-12
0 Images製品番号: HY-184027CAS 番号: 2841468-09-3IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI).
-
Anti-inflammatory agent 15
0 Images製品番号: HY-144737CAS 番号: 474516-87-5Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research.
-
Anti-inflammatory agent 111
0 Images製品番号: HY-181155Anti-inflammatory agent 111 is a potent anti-inflammatory agent. Anti-inflammatory agent 111 reduces Lipopolysaccharides (LPS) (HY-D1056)-induced i-NOS and COX-2 protein expression, decreases nitric oxide, IL-6, and TNF-α production. Anti-inflammatory agent 111 maintains normal cell viability at bioactive concentrations.Anti-inflammatory agent 111 can be used for the research of inflammation-related disorders.
-
TLR7/8/9 antagonist-3
0 Images製品番号: HY-187531CAS 番号: 2403782-38-5TLR7/8/9 antagonist-3 is an orally active antagonist of TLR7, TLR8 and TLR9, with human IC50 values of 0.008 μM, 0.006 μM and 0.072 μM, respectively. TLR7/8/9 antagonist-3 blocks agonist-induced activation of hTLR7, hTLR8, hTLR9, mTLR7 and mTLR9, and reduces serum IFNα and TNFα levels. TLR7/8/9 antagonist-3 can be used in the research of autoimmune diseases.
-
H-Hyp-Leu-OH
0 Images製品番号: HY-P12327CAS 番号: 637030-43-4H-Hyp-Leu-OH is a linear dipeptide of hydroxyproline-leucine with anti-inflammatory and antioxidant activities. H-Hyp-Leu-OH inhibits NO, IL-1β, IL-6, and TNF-α in macrophages, and upregulates IL-10. H-Hyp-Leu-OH extends lifespan, improves exercise capacity, reduces ROS and MDA, and increases SOD, CAT, and GSH-Px. H-Hyp-Leu-OH can be used for epithelial ovarian cancer and antioxidant-related research.
-
SLP7111228
0 Images製品番号: HY-120152CAS 番号: 1449765-82-5SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension.
-
Carveol (Standard)
0 Images製品番号: HY-W017370RCAS 番号: 99-48-9Carveol (Standard) is the analytical standard of Carveol. This product is intended for research and analytical applications. Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke.
-
TLR7/8 agonist 14
0 Images製品番号: HY-179336TLR7/8 agonist 14 is a TLR7 and TLR8 agonist with EC50 values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma.
-
TNX-1500
0 Images製品番号: HY-P991921TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection[1][2].
-
Cot-IN-4
0 Images製品番号: HY-178726CAS 番号: 1984784-10-2Cot-IN-4 (compound 32) is a potent cancer osaka thyroid (COT) kinase inhibitor with an IC50 of 6 nM. Cot-IN-4 inhibits the phosphorylation of ERK (IC50: 60 nM) and inhibits TNFα release (IC50: 60 nM). Cot-IN-4 also inhibits the formation of the pro-inflammatory cytokine IL-1β (IC50: 0.2 μM) in Uric acid (HY-B2130)-stimulated macrophages. Cot-IN-4 can be used for the study of inflammatory diseases.
-
N-Desmethyl clomipramine
0 ImagesN-Desmethyl clomipramine (Desmethylclomipramine; Norclomipramine) is the orally active major active metabolite of the tricyclic antidepressant Clomipramine (HY-B0457A), possessing multiple activities including anti-inflammatory, antioxidant, antibacterial, and antiparasitic effects. N-Desmethyl clomipramine blocks autophagosome-lysosome fusion, leading to the accumulation of LC3-II, p62, ATG7, WIPI2, and ATG5-12, reactivates the p53/p21 pathway, induces apoptosis through C-PARP and C-CAS3, and inhibits the proliferation, migration, and invasion of renal cancer cells. N-Desmethyl clomipramine inhibits LdTOPIA, inducing R-loop accumulation in the nucleus of Leishmania, ultimately causing parasite death. N-Desmethyl clomipramine can be used for research on depression, metastatic renal cell carcinoma, and leishmaniasis.
